Gold prices dip as markets digest Fed outlook; silver falls from record high
Investing.com - H.C. Wainwright has reiterated a Buy rating and $4.00 price target on Quantum-Si Inc. (NASDAQ:QSI) following the company’s investor day on November 19. This target represents a potential 223% upside from the current price of $1.24, though InvestingPro data shows the stock has fallen 9.49% over the past week amid high volatility (Beta of 2.96).
The investment firm highlighted Quantum-Si’s next-generation protein sequencing system, Proteus, which offers significant advantages over its current commercial product, Platinum/Platinum Pro. Proteus is expected to expand the company’s market reach beyond basic research labs to academic medical labs, drug development, healthcare, agriculture, and defense industries. This market expansion could be crucial for the company, which has shown strong revenue growth of 40.2% over the last twelve months, though with a modest $3.18 million in total revenue.
H.C. Wainwright identified Proteus’s ability to detect post-translational modifications (PTMs) as its most notable capability, using three different methods: kinetics, pre-recognition, and direct N-terminal amino acid detection. The system addresses limitations of mass spectrometry, the current gold standard for PTM detection, by offering straightforward quantification, simplified workflow, and direct PTM site identification.
While Quantum-Si has not released an exact list price for Proteus, management indicated a range of $300,000-$500,000, which is 3-5 times higher than Platinum’s $100,000 price point but still below the over $1 million price of mass spectrometry systems currently used for protein sequencing.
H.C. Wainwright believes the PTM detection capabilities and other improvements in Proteus will attract a broader user base and justify the higher price point compared to the company’s existing Platinum system.
In other recent news, Quantum-Si Incorporated reported its third-quarter 2025 earnings, which fell short of analyst expectations. The company posted a loss per share of -$0.17, missing the forecasted -$0.13, and recorded revenue of $550,000, below the anticipated $599,330. During its Investor & Analyst Day, Quantum-Si also announced significant progress on its Proteus protein analysis platform. The company completed over 50 sequencing runs on the Proteus prototype systems, achieving this milestone ahead of its year-end 2025 target. Early data from these runs reportedly meet or exceed the performance of the current Platinum Pro system. Additionally, Quantum-Si plans to launch the Proteus platform by the end of 2026, with an Early Access Program set to begin in summer 2026. The platform is expected to cover 18 amino acids upon launch.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.